Article

Study: Innovative Active Learning Increases Confidence, Knowledge of Pharmacists Managing CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

Key Takeaways

  • Role-specific education for pharmacists is crucial to address the growing complexity of oncology treatments and improve patient outcomes.
  • Two educational programs were developed: an electronic article with interactive case studies and a live virtual symposium with counseling videos.
SHOW MORE

The objective of the study was to develop an education program that increased confidence and knowledge of pharmacists managing CDK4/6 inhibitors.

Education based on specific roles and practice settings for pharmacists is necessary to manage diverse needs, thus enhancing patient outcomes, according to a poster presented at HOPA Ahead 2020.

The objective of the study was to develop an education program that increased confidence and knowledge of pharmacists managing CDK4/6 inhibitors. There is a great need for effective education to match the annual growth and complexity of oncology FDA approvals, according to poster.

In early 2019, 2 collaborative programs were launched, including:

  • A 2.5-credit hour electronic article incorporated cases with patient counseling videos. Case studies were used to foster application of clinical strategies to practice scenarios with interactive decision trees to stimulate real-life management of adverse effects (AEs).
  • A 1.5-hour live virtual symposium embedded counseling videos based on real-life scenarios in 3 settings of patient-centered pharmacist care. Videos were used to highlight significant AEs and showed therapy-specific challenges in various settings.

The educational objectives were to distinguish current treatments strategies for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-advanced breast cancer; examine the efficacy, safety, and mechanism of action of CDK4/6 inhibitors; and identify appropriate AE management, including communication strategies for patients receiving CDK4/6 inhibitors.

Data were analyzed 12 months after launch in February 2020, with 1888 pharmacists completing activities for Accreditation Council for Pharmacy Education credit. Self-identified practice settings included 42.5% retail, 25.3% health-system, and 12.0% specialty pharmacy.

Correlating pre- and post- assessment case-based questions focused on a lab value AE showed a knowledge increase of 51% correct responses to 88% with the use of simulated decision case and video. Pre- and post-assessment case-based questions on counseling for a clinically significant interaction demonstrated a knowledge increase of 34% to 75% with use of a video-embedded case and simulation.

In the pre-activity phase, 51% of learners identified themselves as moderately, very, or extremely confident in using treatment strategies for HR-positive/HER2-advanced breast cancer compared with 85% post-activity.

The study authors concluded that after completing 1 or both activities, pharmacists saw an increase in confidence, knowledge, and competence. The use of innovative videos and adaptive case simulation sets a precedent in designing active education using clinical scenarios applicable to multiple oncology practice settings, according to the poster.

REFERENCE

Innovative Active Learning Increases Confidence and Knowledge of Pharmacists Managing CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer (BC) Poster Presentation. HOPA conference. Published March 12, 2020. https://www.eventscribe.com/2020/HOPAahead/PosterTitles.asp?pfp=PosterTitles. Accessed May 6, 2020.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue